Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2420306 | 0.98 | L3MBTL1 (0.47) | L3MBTL1HTR3ANUDT1HTR2CAURKA | |
| SCHEMBL1576816 | 0.80 | L3MBTL1 (0.67) | L3MBTL1NUDT1HTR2CHDAC6AXL | |
| SCHEMBL22490650 | 0.80 | L3MBTL1 (0.43) | L3MBTL1HTR3ANUDT1HTR2CAURKA | |
| SCHEMBL1348354 | 0.80 | L3MBTL1 (0.41) | L3MBTL1AURKAHDAC6ALDH1A1TNKS | |
| SCHEMBL14006669 | 0.78 | NUDT1 (0.47) | L3MBTL1HTR3ANUDT1AURKAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1369700 | 0.78 | L3MBTL1 (0.65) | L3MBTL1NUDT1HTR2CHDAC6AXL | |
| SCHEMBL26650673 | 0.77 | L3MBTL1 (0.49) | L3MBTL1NUDT1HTR2CAURKAAXL | |
| SCHEMBL16705075 | 0.77 | L3MBTL1 (0.62) | L3MBTL1HTR3ANUDT1HTR2CALDH1A1 | |
| SCHEMBL15747098 | 0.77 | L3MBTL1 (0.49) | L3MBTL1NUDT1HTR2CAXLTNKS | |
| SCHEMBL25974824 | 0.77 | L3MBTL1 (0.41) | L3MBTL1HTR3ANUDT1HTR2CAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222147-A1 | HETEROCYCLIC GCN2 MODULATORS | HIBERCELL, INC. (US) | 2021-11-04 | — | — | WO | claimed |
| EP-4709724-A1 | ANTICONVULSIVE COMPOUNDS AND USES THEREOF | Jazz Pharmaceuticals Research UK Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2025-10-16 | — | — | US | disclosed |
| CN-119591599-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119591600-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4472968-A1 | INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2024-12-11 | — | — | EP | disclosed |
| CN-114423756-B | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024236275-A1 | ANTICONVULSIVE COMPOUNDS AND USES THEREOF | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2024-11-21 | — | — | WO | disclosed |
| CN-118974036-A | Inhibitors of RAF kinase | 皮埃尔法布雷医药公司 | 2024-11-15 | — | — | CN | disclosed |
| US-8722676-B2 | Bicyclic piperazine compounds | GENENTECH, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013067260-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067260-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011072064-A1 | S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | L3MBTL1 577/4885HTR3A 3615/4885NUDT1 2571/4885 |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | L3MBTL1 3833/4885HTR3A 3538/4885NUDT1 2326/4885 |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | ATR, CHEK1, CHEK2 | L3MBTL1 560/4885HTR3A 3677/4885NUDT1 2559/4885 |
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | BTK, LCK, SYK | L3MBTL1 3862/4885HTR3A 3876/4885NUDT1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.